Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TFRC
REST API REST API
Homo sapiens
TFRC is differentially expressed in 369 experiments: 131 organism parts: placenta, bone marrow, ... (129 more);, 233 disease states: normal, chronic myelogenous leukemia, ... (231 more);, 128 cell types 458 cell lines 40 compound treatments and 87 other conditions.
Synonyms TFR1, CD71
Orthologs TFRC (Gallus gallus)   tfr1a (Danio rerio)   tfr1b (Danio rerio)   TFRC (2 of 3) (Danio rerio)   TFRC (Bos taurus)   VPS70 (Saccharomyces cerevisiae)   Tfrc (Mus musculus)   Tfrc (Rattus norvegicus)   tfrc (Xenopus laevis)   TFR1_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, response to copper ion, Hsp70 protein binding, acute-phase response, membrane, peptidase activity, chaperone binding, extracellular region, response to hypoxia, response to nutrient, coated pit, integral to plasma membrane, aging, receptor activity, cytoplasmic membrane-bounded vesicle, endosome, perinuclear region of cytoplasm, proteolysis, cellular iron ion homeostasis, transmembrane transport, cell surface, mitochondrion, endocytosis, extracellular vesicular exosome, recycling endosome membrane, transferrin transport, response to iron ion, positive regulation of bone resorption, transferrin receptor activity, response to retinoic acid, response to inorganic substance, interspecies interaction between organisms, response to organic substance, response to manganese ion, melanosome, osteoclast differentiation
InterPro Term Peptidase_M28, Protease-assoc_domain, TFR-like_dimer_dom
UniProt Accession P02786, F5H6B1, F8WBE5
Search EB-eye ENSG00000072274
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-MEXP-433, ... (36 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-19397, E-GEOD-4717, ... (44 experiments)

Factor Value U/D Experiments
K562
3
E-MTAB-37, E-GEOD-96, E-GEOD-24147
MCF-7
1
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
PC3
2
E-GEOD-5258, E-GEOD-14464
BT-474
2
E-GEOD-3529, E-GEOD-5823
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MDAMB175VII
2
E-MTAB-37, E-MTAB-62
452 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-21668, E-MEXP-750, E-GEOD-20677, ... (60 experiments)

Factor Value U/D Experiments
macrophage
3
E-GEOD-8286, E-GEOD-3982, E-GEOD-22373
plasma cell
2
E-MEXP-2360, E-GEOD-6691
721 B lymphoblast
1
2
E-AFMX-5, E-TABM-145
monocyte
3
4
E-MEXP-583, E-MEXP-2019, E-GEOD-11755, E-GEOD-5099, E-GEOD-8286, ... (7 experiments)
stromal cell
1
2
E-GEOD-1460, E-MEXP-2034, E-GEOD-10797
CD14+ monocyte
1
2
E-AFMX-5, E-MEXP-1600, E-TABM-145
122 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-TABM-15, E-MEXP-2280, ... (70 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-62, E-MTAB-37, E-MEXP-231, E-GEOD-2514
Burkitt's lymphoma
3
E-GEOD-96, E-GEOD-1880, E-MTAB-37
chronic myelogenous leukemia
1
3
E-GEOD-96, E-MTAB-37, E-MTAB-62, E-GEOD-5550
septic shock
2
E-GEOD-9692, E-GEOD-8121
AIDS-KS, HIV+, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
acute lymphoblastic leukemia
2
E-GEOD-96, E-MTAB-62
227 more value(s).


Compound treatment

studied in E-GEOD-5741, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (25 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-GEOD-3720, E-TABM-868
sapphyrin PCI-2055
1
E-GEOD-6400
sapphyrin PCI-2051
1
E-GEOD-6400
non-steroidal anti-inflammatory drugs
1
E-GEOD-1919
TNF
1
E-GEOD-15205
nickel(II) chloride hexahydrate
1
E-GEOD-6907
34 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
44
2
1
E-GEOD-21653
78
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MEXP-1251, E-GEOD-19246, E-GEOD-4619, E-GEOD-1563, ... (14 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-MEXP-2359, E-GEOD-6236, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-22148, E-TABM-147, ... (9 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-MEXP-1437, E-GEOD-1045, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, E-GEOD-837, ... (17 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-GEOD-2466, E-MEXP-2069, ... (37 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-980, ... (7 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1460, E-GEOD-2487, E-GEOD-5820, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-GEOD-12438, E-GEOD-1676, E-MEXP-101, ... (10 experiments)

Sample preparation
studied in E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7540, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-22541, E-GEOD-1561, ... (8 experiments)

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.426 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM